Back to Search Start Over

Expanding the inhibitor space of the WWP1 and WWP2 HECT E3 ligases.

Authors :
Dudey AP
Rigby JM
Hughes GR
Stephenson GR
Storr TE
Chantry A
Hemmings AM
Source :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2024 Dec; Vol. 39 (1), pp. 2394895. Date of Electronic Publication: 2024 Sep 02.
Publication Year :
2024

Abstract

The HECT E3 ubiquitin ligases 1 (WWP1) and 2 (WWP2) are responsible for the ubiquitin-mediated degradation of key tumour suppressor proteins and are dysregulated in various cancers and diseases. Here we expand their limited inhibitor space by identification of NSC-217913 displaying a WWP1 IC <subscript>50</subscript> of 158.3 µM (95% CI = 128.7, 195.1 µM). A structure-activity relationship by synthesis approach aided by molecular docking led to compound 11 which displayed increased potency with an IC <subscript>50</subscript> of 32.7 µM (95% CI = 24.6, 44.3 µM) for WWP1 and 269.2 µM (95% CI = 209.4, 347.9 µM) for WWP2. Molecular docking yielded active site-bound poses suggesting that the heterocyclic imidazo[4,5- b ]pyrazine scaffold undertakes a π-stacking interaction with the phenolic group of tyrosine, and the ethyl ester enables strong ion-dipole interactions. Given the therapeutic potential of WWP1 and WWP2, we propose that compound 11 may provide a basis for future lead compound development.

Details

Language :
English
ISSN :
1475-6374
Volume :
39
Issue :
1
Database :
MEDLINE
Journal :
Journal of enzyme inhibition and medicinal chemistry
Publication Type :
Academic Journal
Accession number :
39223706
Full Text :
https://doi.org/10.1080/14756366.2024.2394895